Approved by FDA as prescription topical solution
Dong-A ST (CEO Min Jang-sung) released “Jublia,” a FDA-approved prescription
topical solution proven to treat toenail fungus, as of June 1, 2017.
Jublia (efinaconazole) has been developed by Japan’s Kaken Pharmaceutical in 2014.
Dong-A ST Co. Ltd and Kaken Pharmaceutical concluded an exclusive distribution
agreement for the topical formulation for onychomycosis in Korea in May 2016. Under the deal, Kaken will grant to Dong-A the exclusive right for development and sales of
the product in Korea.
Toenail fungus or onychomycosis is the “athlete’s foot of the nails” that occurs when bacteria that cause athlete's foot infects the nails of the feet and hands. Toenail fungus lives underneath the nail, in the skin of the nail bed. Toenail fungus is more than a cosmetic concern Jublia is applied on, around, and under the nail to get to the site of infection. Your toenails should be clean and dry before you apply Jublia.
Jublia was approved by the FDA in 2014 for the treatment of nail fungus.
Jublia is applied directly to affected nails. It has been reported that over 30 million Americans suffer from toenail fungus, which leads to thickening, yellowing and discomfort.
Oral antifungal drugs are available by prescription but have serious
side effects and frequently interact with other medications..
Jublia shows outstanding cure rates than most oral anti-fungus agents.
Jublia has low-level side effects, while boasting advantages of topical solutions
The product has potential side effects, but because Jublia is applied to the nails and nail beds, they are not expected to affect the liver or interact with other drugs.
In June 2014, the Food and Drug Administration, FDA) gave a green light to Jublia. A year later, the drug’s sales in North America amounted to approximately US$340 million
(405 billion won). In Japan, the product recorded sales of 19.9 billion yen in 2015.
As such, Jublia has became No. 1 anti-toenail fungus agent selling in North America and Japan.
In Korea, an estimated 1.2 million people suffer from toenail fungus. Left untreated,
an infection could spread to other toenails, skin, or even your fingernails. Kim Jin-hoon,
marketing chief at Dong-A ST, said that Jublia, with its outstanding efficacy, is expected to
make significant contributions to treatment of those with toenail fungus.
How to apply: Remove the cap from the Jublia bottle. Hold the bottle upside down directly
over the affected toenail. By turning the bottle upside down, the entire brush
will become moistened with the solution. Apply one drop of Jublia onto the toenail.
Do not squeeze the bottle, or press or rub the brush firmly against the toenail
while applying JUBLIA. Apply Jublia to affected toenails once daily for 48 weeks,
using the integrated flow-trough brush applicator. When apply Jublia, ensure that the
toenail, the toenail folds, toenail bed, etc. are completely covered.
New Drug Research Center
Dong-A ST’s New-Drug Research Center, based on our accumulated new-drug
development technologies and experiences, has selected research on products
related to QOL(quality of life) as the key area, and is exerting all-out R&D efforts. For instance, we are bolstering the areas of digestive-disorder drugs, including Stillen, and of urinary-disorder drugs, including Zydena, while expanding the research area for endocrine-metabolic disorders, including diabetes, thus striving to create global brands.